Bulk Manufacturer of Controlled Substances Application: S&B Pharma LLC, 11955-11956 [2023-03827]
Download as PDF
<![CDATA[
11955
Federal Register / Vol. 88, No. 37 / Friday, February 24, 2023 / Notices
Commission did not find any other
circumstances that would warrant
conducting full reviews.1 Accordingly,
the Commission determined that it
would conduct expedited reviews
pursuant to section 751(c)(3) of the
Tariff Act of 1930 (19 U.S.C.
1675(c)(3)).2
For further information concerning
the conduct of these reviews and rules
of general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A, D, E, and F (19 CFR part
207).
Staff report.—A staff report
containing information concerning the
subject matter of the reviews has been
placed in the nonpublic record, and will
be made available to persons on the
Administrative Protective Order service
list for these reviews on March 3, 2023.
A public version will be issued
thereafter, pursuant to section
207.62(d)(4) of the Commission’s rules.
Written submissions.—As provided in
section 207.62(d) of the Commission’s
rules, interested parties that are parties
to the reviews and that have provided
individually adequate responses to the
notice of institution,3 and any party
other than an interested party to the
reviews may file written comments with
the Secretary on what determination the
Commission should reach in the
reviews. Comments are due on or before
March 8, 2023 and may not contain new
factual information. Any person that is
neither a party to the five-year reviews
nor an interested party may submit a
brief written statement (which shall not
contain any new factual information)
pertinent to the reviews by March 8,
2023. However, should the Department
of Commerce (‘‘Commerce’’) extend the
time limit for its completion of the final
results of its reviews, the deadline for
comments (which may not contain new
factual information) on Commerce’s
final results is three business days after
the issuance of Commerce’s results. If
comments contain business proprietary
information (BPI), they must conform
with the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s Handbook on
ddrumheller on DSK120RN23PROD with NOTICES
1A
record of the Commissioners’ votes, the
Commission’s statement on adequacy, and any
individual Commissioner’s statements will be
available from the Office of the Secretary and at the
Commission’s website.
2 Chairman Johanson voted to conduct full
reviews.
3 The Commission has found the responses
submitted on behalf of Core Pipe Products, Inc.,
Felker Brothers Corporation, and Jero Inc. to be
individually adequate. Comments from other
interested parties will not be accepted (see 19 CFR
207.62(d)(2)).
VerDate Sep<11>2014
18:15 Feb 23, 2023
Jkt 259001
Filing Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the reviews must be
served on all other parties to the reviews
(as identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Authority: These reviews are being
conducted under authority of title VII of
the Tariff Act of 1930; this notice is
published pursuant to section 207.62 of
the Commission’s rules.
By order of the Commission.
Issued: February 17, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023–03803 Filed 2–23–23; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on January 30, 2023,
Stepan Company, 100 West Hunter
Avenue, Maywood, New Jersey 07607–
1021 applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
Controlled substance
Drug
code
Schedule
[Docket No. DEA–1158]
Coca Leaves ................
Importer of Controlled Substances
Application: Stepan Company
The company plans to import the
listed controlled substance to bulk
manufacture other controlled substances
for distribution to its customers. No
other activities for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Stepan Company has applied
to be registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 27, 2023. Such
persons may also file a written request
for a hearing on the application on or
before March 27, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
DATES:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
9040
II
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023–03841 Filed 2–23–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1151]
Bulk Manufacturer of Controlled
Substances Application: S&B Pharma
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
E:\FR\FM\24FEN1.SGM
24FEN1
11956
Federal Register / Vol. 88, No. 37 / Friday, February 24, 2023 / Notices
S&B Pharma LLC has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 25, 2023. Such
persons may also file a written request
for a hearing on the application on or
before April 25, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 10, 2023, S&B
Pharma LLC, 405 South Motor Avenue,
Azusa, California 91702, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
SUMMARY:
Controlled substance
ddrumheller on DSK120RN23PROD with NOTICES
Marihuana .....................
Tetrahydrocannabinols
Amphetamine ...............
Methamphetamine ........
Lisdexamfetamine ........
Methylphenidate ...........
Pentobarbital ................
4-Anilino-N-Phenethyl4-Piperidine (ANPP).
Tapentadol ....................
Fentanyl ........................
Drug
code
Schedule
7360
7370
1100
1105
1205
1724
2270
8333
I
I
II
II
II
II
II
II
9780
9801
II
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates for formulation and
analytical development purposes or for
sale to its customers. In reference to
drug codes 7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
VerDate Sep<11>2014
18:15 Feb 23, 2023
Jkt 259001
drug codes are authorized for this
registration.
Controlled substance
Drug
code
Schedule
Matthew Strait,
Deputy Assistant Administrator.
Ecgonine .......................
[FR Doc. 2023–03827 Filed 2–23–23; 8:45 am]
The company plans to produce the
listed controlled substance in bulk to be
used in the manufacture of the DEA
exempt products. No other activities for
these drug codes are authorized for this
registration.
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1149]
9180
II
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2023–03820 Filed 2–23–23; 8:45 am]
Bulk Manufacturer of Controlled
Substances Application: Siemens
Healthcare Diagnostics, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
BILLING CODE P
DEPARTMENT OF JUSTICE
AGENCY:
Drug Enforcement Administration
[Docket No. DEA–1157]
Siemens Healthcare
Diagnostics, Inc. has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 25, 2023. Such
persons may also file a written request
for a hearing on the application on or
before April 25, 2023.
ADDRESSES: The Drug Enforcement
Administration (DEA) requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.’’
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 11, 2023,
Siemens Healthcare Diagnostics Inc.,
100 GBC Drive, Mailstop 514, Newark,
Delaware 19702–2461, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
SUMMARY:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Bulk Manufacturer of Controlled
Substances Application: Sterling
Wisconsin, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Sterling Wisconsin, LLC has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 25, 2023. Such
persons may also file a written request
for a hearing on the application on or
before April 25, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 6, 2023,
SUMMARY:
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 88, Number 37 (Friday, February 24, 2023)]
[Notices]
[Pages 11955-11956]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03827]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1151]
Bulk Manufacturer of Controlled Substances Application: S&B
Pharma LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
[[Page 11956]]
SUMMARY: S&B Pharma LLC has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
April 25, 2023. Such persons may also file a written request for a
hearing on the application on or before April 25, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on January 10, 2023, S&B Pharma LLC, 405 South Motor
Avenue, Azusa, California 91702, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
Amphetamine............................ 1100 II
Methamphetamine........................ 1105 II
Lisdexamfetamine....................... 1205 II
Methylphenidate........................ 1724 II
Pentobarbital.......................... 2270 II
4-Anilino-N-Phenethyl-4-Piperidine 8333 II
(ANPP).
Tapentadol............................. 9780 II
Fentanyl............................... 9801 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for the internal use intermediates for formulation and
analytical development purposes or for sale to its customers. In
reference to drug codes 7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetic. No other activities for these drug codes are
authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023-03827 Filed 2-23-23; 8:45 am]
BILLING CODE P
